More Videos
SPECIAL REPORT
- Food Network, HGTV Drive Scripps Networks' Upside Surprise
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- U.S. Markets Gain 3% for the Week Despite 10.2% Unemployment
- Disney's 'Carol' Tests Widest 3-D Release Ever
- Stimulus II? Jobs Tax Credit=Cash For Clunkers
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Is Misery Alive And Well in Your Office?
- Consumers Haven't Changed, They Are Just Pickier
- For the Jobless, 10% is Harder Than Before
- Week Ahead: Stocks Search for Catalyst in Quiet Week
- Outlook: Dollar Likely to Ride Higher on Bleak Jobs Report
- Geithner: More Stimulus, Not a Bank Tax
- Windfall is Seen as Bank Bonuses are Paid in Stock
- Buffett's Berkshire Hathaway Says Net Income Tripled
- Cramer: Earnings, IPOs Dominate Next Week
- Buying Fear: How to Own Volatility
- Administration Rejects Plan to Buy Fannie Mae Credits
RSS FEED
Pharma's Market
Text Size 
 |
AP |
Well, he might have spoken too soon.
After putting out its disappointing 2009 earnings guidance, Merck Chairman and CEO Dick Clark wrapped up the conference call this morning by saying, "We are in the midst of extraordinary times. There is uncertainty in all areas of the market and the pharmaceutical markets are no exception."
That comment was preceded by more detailed remarks from MRK's [MRK
Loading...
()
] Chief Financial Officer Peter Kellogg, who said that inside and outside the U.S., unit volume (prescription numbers) has slowed "as we've come through the second half of this year." But he added the caveat that he couldn't tell yet whether that issue is product specific to Merck or a sector-wide problem.
In his research note to clients, though, UBS' Patel also pointed out, "During the last 6 recessions since 1960, there wasn't a single year when either overall drug spend or out-of-pocket drug spend has declined. Note, out of pocket drug spend was 96 percent of total drug spend in 1960; it has fallen to 22 percent in 2006." Could this recession be an anomaly?
Merck puts out its financial guidance a week ahead of its annual research and development update meeting (Dec. 9). Eli Lilly [LLY
Loading...
()
] is also holding an analyst meeting next week (Dec. 11), so we could get additional color there about whether the slower prescription trend Merck says it's seeing is company specific or more widespread. I'll be at both meetings, where I'll be doing live interviews with the CEOs.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes